Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
RGX-111-5101 is a long-term follow up study that evaluates the long-term safety and efficacy of RGX-111 in participants who have received RGX-111 (a gene therapy intended to deliver a functional copy of the alpha-L-iduronidase gene (IDUA) to the central nervous system) in a separate parent study.
This is a prospective, multicenter, long-term observational, follow-up study to evaluate the long-term safety and efficacy of RGX-111 after a single administration. Eligible participants are those who previously participated in a clinical study where they received a single intracisternal (IC) or intraventricular (IVR; also referred to as intracerebroventricular [ICV]) infusion of RGX-111. Enrollment of each participant in this study should occur on the same day or after the participant has completed the end of study (EOS) visit or early discontinuation visit (EDV) from a previous (parent) clinical study. Participants will be followed for up to five years after RGX-111 administration (inclusive of the parent study). No treatment will be directed under this observational study. The total study duration for each participant may vary depending on when s/he enrolls in the current study following RGX-111 administration in the parent study.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| RGX-111 Recipients | Subjects who have received RGX-111 in a separate parent study. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| No Intervention | Genetic | Observational study |
|
| Measure | Description | Time Frame |
|---|---|---|
| Evaluation of the long-term safety of RGX-111 | Incidences of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) over time using CTCAE Version 5.0 | 5 years inclusive of parent study |
| Measure | Description | Time Frame |
|---|---|---|
| Long-term impact of RGX-111 on neurodevelopmental parameters of cognitive, behavioral, and adaptive function (WASI-II) | Change from baseline in neurodevelopmental parameters as measured by the Wechsler Abbreviated Scale of Intelligence (WASI-II). The WASI-II assesses intelligence in individuals from ages 6 to 90 years old. The assessment will yield composite scores that estimate verbal comprehension and perceptual reasoning abilities. The age equivalent scores are also provided for each of the subtests. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Received RGX-111 in a separate parent trial.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Children's Hospital of Orange County | Orange | California | 92868 | United States | ||
| Hospital de Clinicas de Porto Alegre |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008059 | Mucopolysaccharidosis I |
| ID | Term |
|---|---|
| D009083 | Mucopolysaccharidoses |
| D002239 | Carbohydrate Metabolism, Inborn Errors |
| D008661 | Metabolism, Inborn Errors |
| D030342 | Genetic Diseases, Inborn |
Not provided
Not provided
Not provided
Not provided
Not provided
| 5 years inclusive of parent study |
| Long-term impact of RGX-111 on neurodevelopmental parameters of cognitive, behavioral, and adaptive function (WPPSI-IV) | Change from baseline in neurodevelopmental parameters as measured by the Wechsler Preschool and Primary Scale of Intelligence Fourth Edition (WPPSI-IV). The WPPSI-IV measures the cognitive development in young children approximately 30 to 91 months in age. This study utilizes the General Ability Index (GAI) comprised of 4 core subtests depending on the child's age; the subtests include receptive vocabulary, block design, information, and quiet assembly for children 3 to 47 months and block design, information, matrix reasoning and similarities for ages 48 to 91 months. The subtests have different scoring ranges, with higher subtest raw scores indicating completion of more complex items but can be normalized from cross-subtest comparison. | 5 years inclusive of parent study |
| Long-term impact of RGX-111 on neurodevelopmental parameters of cognitive, behavioral, and adaptive function (BSID-III) | Change from baseline in neurodevelopmental parameters as measured by the Bayley Scales of Infant and Toddler Development, Third Edition. The BSID-III assesses children aged 1 to 42 months across several domains to give a holistic view of the child's development and potential delays. Participants will be assessed for the Cognitive, Language and Motor domains of the BSID-III. The domains have different scoring ranges but can be normalized for cross-domain comparisons. | 5 years inclusive of parent study |
| Long-term impact of RGX-111 on neurodevelopmental parameters of cognitive, behavioral, and adaptive function (VABS-III) | Change from baseline adaptive behavior as measured by Vineland Adaptive Behavior Scales Third Edition (VABS-III). The VABS-III assesses adaptive behavior in individuals from infancy to age 90 years. In this study, 4 domains of Communication, Daily Living Skills, Socialization, and Motor Skills will be assessed. The domains have different scoring ranges, with higher subdomain raw scores indicating greater function, but can be normalized for cross-domain comparisons. | 5 years inclusive of parent study |
| Pharmacodynamic Effect of RGX-111 on CSF Biomarkers (HS) | To assess the pharmacodynamic effect of RGX-111 on Heparan Sulfate (HS) levels measures by lumbar puncture. | 5 years inclusive of parent study |
| Pharmacodynamic Effect of RGX-111 on CSF Biomarkers (IDUA) | To assess the pharmacodynamic effect of RGX-111 on α-L-iduronidase (IDUA) levels measures by lumbar puncture. | 5 years inclusive of parent study |
| Pharmacodynamic Effect of RGX-111 on Plasma Biomarkers (HS) | To assess the pharmacodynamic effect of RGX-111 on Heparan Sulfate (HS) levels measures by plasma collection. | 5 years inclusive of parent study |
| Pharmacodynamic Effect of RGX-111 on Plasma Biomarkers (IDUA) | To assess the pharmacodynamic effect of RGX-111 on α-L-iduronidase (IDUA) levels measures by plasma collection. | 5 years inclusive of parent study |
| Pharmacodynamic Effect of RGX-111 on Urine Biomarkers (GAGs) | To assess the pharmacodynamic effect of RGX-111 on glycosaminoglycans (GAGs) levels measured by urine analysis. | 5 years inclusive of parent study |
| Porto Alegre |
| Rio Grande do Sul |
| 90035-903 |
| Brazil |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D016464 | Lysosomal Storage Diseases |
| D017520 | Mucinoses |
| D003240 | Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |